Monkeying around with HIV vaccines: Using rhesus macaques to define 'gatekeepers' for clinical trials

Nature Reviews Immunology

Volumn 9, Issue 10, 2009, Pages 717-728

  Shedlock, Devon J ^a   Silvestri, Guido ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ANTIBODY TITER; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL RESEARCH; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; MACACA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURAL HOMOLOGY; VERTICAL TRANSMISSION; VIROGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HIV; HUMANS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 70349470783     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2636     Document Type: Review

References (131)

1. Thomas, C. Roadblocks in HIV research: five questions. Nature Med. 15, 855-859 (2009).
2. Gardner, M. B. & Luciw, P. A. Animal models of AIDS. FASeB J. 3, 2593-2606 (1989).
3. Sekaly, R. P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. exp. Med. 205, 7-12 (2008).
4. Ambrose, Z., KewalRamani, V. N., Bieniasz, P. D. & Hatziioannou, T. HIV/AIDS: in search of an animal model. Trends Biotechnol. 25, 333-337 (2007).
5. Lackner, A. A. & Veazey, R. S. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu. Rev. Med. 58, 461-476 (2007).
6. Morgan, C. et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5, e173 (2008).
7. Williams, R. et al. Nonhuman primate models of NeuroAIDS. J. Neurovirol. 14, 292-300 (2008).
8. Baenziger, S. et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γc-/- mice. Proc. Natl Acad. Sci. USA 103, 15951-15956 (2006).
9. Silvestri, G. et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18, 441-452 (2003).
10. Paiardini, M., Frank, I., Pandrea, I., Apetrei, C. & Silvestri, G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev. 10, 36-46 (2008).
11. Silvestri, G., Paiardini, M., Pandrea, I., Lederman, M. M. & Sodora, D. L. Understanding the benign nature of SIV infection in natural hosts. J. Clin. Invest. 11 7 , 3148-3154 (2007).
12. Lubeck, M. D. et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med. 3, 651-658 (1997).
13. Boyer, J. D. et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3, 526-532 (1997). This paper showed the efficacy of an HIV DNA vaccine in protecting chimpanzees from infection with an HIV-1 SF2 virus.
14. Kutzler, M. A. & Weiner, D. B. DNA vaccines: ready for prime time? Nature Rev. Genet. 9, 776-788 (2008).
15. Wang, B. et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 90, 4156-4160 (1993).
16. Berman, P. W. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625 (1990).
17. Berman, P. W. et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173, 52-59 (1996).
18. Fultz, P. N. et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 256, 1687-1690 (1992).
19. Girard, M. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. USA 88, 542-546 (1991).
20. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
21. Watanabe, M. E. Skeptical scientists skewer VaxGen statistics. Nature Med. 9, 376 (2003).
22. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
23. Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
24. Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
25. Liang, X. et al. Vectored Gag and Env but not Ta t show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J. Virol. 79, 12321-12331 (2005).
26. Casimiro, D. R. et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79, 15547-15555 (2005).
27. Horton, H. et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76, 7187-7202 (2002).
28. Ourmanov, I., Bilska, M., Hirsch, V. M. & Montefiori, D. C. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J. Virol. 74, 2960-2965 (2000). (Pubitemid 30117614)
29. Ourmanov, I. et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74, 2740-2751 (2000). (Pubitemid 30117585)
30. Robb, M. L. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372, 1857-1858 (2008).
31. Gardner, M. B. & Luciw, P. A. Macaque models of human infectious disease. ILAR J. 49, 220-255 (2008).
32. McKenna, P. et al. The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathog. 4, e20 (2008).
33. Scott, W. J., Wilson, J. G. & Helm, F. C. A metabolite of a structural analog of thalidomide lacks teratogenic effect in pregnant rhesus monkeys. Teratology 22, 183-185 (1980).
34. Turner, C. R. et al. In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J. Clin. Invest. 97, 381-387 (1996).
35. Hogan, M. B., Harris, K. E., Protter, A. A. & Patterson, R. A bradykinin antagonist inhibits both bradykinin- and the allergen-induced airway response in primates. Proc. Assoc. Am. Physicians 109, 269-274 (1997).
36. Coleman, R. A. Current animal models are not predictive for clinical asthma. Pulm. Pharmacol. Ther. 12, 87-89 (1999).
37. Daza-Vamenta, R., Glusman, G., Rowen, L., Guthrie, B. & Geraghty, D. E. Genetic divergence of the rhesus macaque major histocompatibility complex. Genome Res. 14, 1501-1515 (2004).
38. Gibbs, R. A. et al. Evolutionary and biomedical insights from the rhesus macaque genome. Science 316, 222-234 (2007)
39. Oshinsky, D. M. Polio: an American Story (Oxford Univ. Press, New York, 2005).
40. Guerrini, A. experimenting with Humans and Animals: from Galen to Animal Rights (Johns Hopkins Univ. Press, Baltimore, 2003).
41. Horstmann, D. M. The poliomyelitis story: a scientific hegira. Yale J. Biol. Med. 58, 79-90 (1985).
42. Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300, 337-339 (2003).
43. Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
44. Janssen, E. M. et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852-856 (2003). This study, together with references 42 and 43, shows that CD4+ T cell help during the acute phase of infection is crucial for the generation of functional CD8+ T cell memory.
45. Goulder, P. J. & Watkins, D. I. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nature Rev. Immunol. 8, 619-630 (2008).
46. Hendel, H. et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162, 6942-6946 (1999).
47. Lambotte, O. et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41, 1053-1056 (2005).
48. Lederman, M. M., Jump, R., Pilch-Cooper, H. A., Root, M. & Sieg, S. F. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology 5, 116 (2008).
49. Miller, C. J. et al. Effect of virus dose and nonoxynol-9 on the genital transmission of SIV in rhesus macaques. J. Med. Primatol. 19, 401-409 (1990).
50. Kreiss, J. et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 268, 477-482 (1992).
51. Van Damme, L. et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360, 971-977 (2002).
52. Van Damme, L. et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. engl. J. Med. 359, 463-472 (2008).
53. Ramjee, G., Govinden, R., Morar, N. S. & Mbewu, A. South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Med. 4, e235 (2007).
54. Roddy, R. E. et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. engl. J. Med. 339, 504-510 (1998).
55. Rustomjee, R., Abdool Karim, Q., Abdool Karim, S. S., Laga, M. & Stein, Z. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS 13, 1511-1515 (1999).
56. Kuller, L., Benveniste, R. E., Watanabe, R., Tsai, C. C. & Morton, W. R. Transmission of SIVMne from female to male Macaca nemestrina. J. Med. Primatol. 21, 299-307 (1992).
57. Miller, C. J. Localization of simian immunodeficiency virus-infected cells in the genital tract of male and female Rhesus macaques. J. Reprod. Immunol. 41, 331-339 (1998).
58. Miller, C. J. et al. Pathology and localization of simian immunodeficiency virus in the reproductive tract of chronically infected male rhesus macaques. Lab. Invest. 70, 255-262 (1994).
59. Garnett, G. P. & Rottingen, J. A. Measuring the risk of HIV transmission. AIDS 15, 641-643 (2001).
60. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. engl. J. Med. 342, 921-929 (2000).
61. Gordon, S. N. et al. Severe depletion of mucosal CD4+ T cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J. Immunol. 179, 3026-3034 (2007).
62. Little, S. J., McLean, A. R., Spina, C. A., Richman, D. D. & Havlir, D. V. Viral dynamics of acute HIV-1 infection. J. exp. Med. 190, 841-850 (1999).
63. Milush, J. M. et al. Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host. J. Immunol. 179, 3047-3056 (2007).
64. Novitsky, V. et al. Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection. J. Acquir. Immune Defic. Syndr. 50, 65-76 (2009).
65. Stekler, J. et al. HIV dynamics in seminal plasma during primary HIV infection. AIDS Res. Hum. Retroviruses 24, 1269-1274 (2008).
66. Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875-5885 (2006).
67. Yeh, W. W. et al. Partial protection of simian immunodeficiency virus (SIV)-infected rhesus monkeys against superinfection with a heterologous SIV isolate. J. Virol. 83, 2686-2696 (2009).
68. Letvin, N. L. & King, N. W. Immunologic and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Acquir. Immune Defic. Syndr. 3, 1023-1040 (1990).
69. Schnittman, S. M. et al. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding. J. Immunol. 141, 4181-4186 (1988).
70. Emini, E. A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
71. Boyer, J. D. et al. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J. Med. Primatol. 25, 242-250 (1996).
72. Bruck, C. et al. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12, 1141-1148 (1994).
73. Girard, M. et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69, 6239-6248 (1995).
74. Estaquier, J. et al. Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc. Natl Acad. Sci. USA 91, 9431-9435 (1994).
75. Gougeon, M. L. et al. Lack of chronic immune activation in HIV-infected chimpanzees correlates with the resistance of T cells to Fas/Apo-1 (CD95)-induced apoptosis and preservation of a T helper 1 phenotype. J. Immunol. 158, 2964-2976 (1997).
76. Koopman, G., Haaksma, A. G., ten Velden, J., Hack, C. E. & Heeney, J. L. The relative resistance of HIV type 1-infected chimpanzees to AIDS correlates with the maintenance of follicular architecture and the absence of infiltration by CD8+ cytotoxic T lymphocytes. AIDS Res. Hum. Retroviruses 15, 365-373 (1999).
77. Schuitemaker, H. et al. Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J. Infect. Dis. 168, 1140-1147 (1993).
78. Zarling, J. M. et al. HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells. J. Immunol. 144, 2992-2998 (1990).
79. Keele, B. F. et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460, 515-519 (2009).
80. Novembre, F. J. et al. Rapid CD4+ T-cell loss induced by human immunodeficiency virus type 1NC in uninfected and previously infected chimpanzees. J. Virol. 75, 1533-1539 (2001).
81. O'Neil, S. P. et al. Progressive infection in a subset of HIV-1-positive chimpanzees. J. Infect. Dis. 182, 1051-1062 (2000).
82. Novembre, F. J. et al. Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J. Virol. 71, 4086-4091 (1997).
83. Maynard, J. E., Berquist, K. R., Krushak, D. H. & Purcell, R. H. Experimental infection of chimpanzees with the virus of hepatitis B. Nature 237, 514-515 (1972).
84. Miller, C. J. et al. Genital mucosal transmission of simian immunodeficiency virus: animal model for heterosexual transmission of human immunodeficiency virus. J. Virol. 63, 4277-4284 (1989).
85. Sutjipto, S. et al. Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals. J. Virol. 64, 2290-2297 (1990).
86. Reimann, K. A. et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 6922-6928 (1996).
87. Nishimura, Y. et al. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl Acad. Sci. USA 101, 12324-12329 (2004).
88. Fields, B. N., Knipe, D. M. & Howley, P. M. Fields' Virology (Wolters Kluwer Health, Philadelphia, 2007).
89. Migueles, S. A. et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009-1021 (2008).
90. Blish, C. A. et al. Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses. J. Virol. 82, 12094-12103 (2008).
91. Wilson, N. A. et al. Vaccine-induced cellular responses control SIV replication after heterologous challenge. J. Virol. 83, 6508-6521 (2009).
92. Butler, D., Lakdawala, M., Richman, D. D., Little, S. J. & Smith, D. G. Cell-free virus in seminal plasma samples is the origin of sexually transmitted HIV among men who have sex with men.16th Conference on Retroviruses and Opportunistic Infections, Montreal [Online abstract](2009).
93. Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Med. 15, 901-906 (2009).
94. Reynolds, M. R. et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. exp. Med. 205, 2537-2550 (2008).
95. Edinger, A. L. et al. Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc. Natl Acad. Sci. USA 94, 4005-4010 (1997).
96. Kirchhoff, F. et al. Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J. Virol. 71, 6509-6516 (1997).
97. Weissman, D. et al. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389, 981-985 (1997).
98. Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552-7557 (2008).
99. Keele, B. F. et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. exp. Med. 206, 1117-1134 (2009).
100. McDermott, A. B. et al. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J. Virol. 78, 3140-3144 (2004).
101. Van Damme, N. et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-252 (2008).
102. Van Damme, N. & Guatelli, J. HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes. Cell. Microbiol. 10, 1040-1057 (2008).
103. Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425-430 (2008).
104. Cullen, B. R. HIV-1 auxiliary proteins: making connections in a dying cell. Cell 93, 685-692 (1998).
105. Bieniasz, P. D. Intrinsic immunity: a front-line defense against viral attack. Nature Immunol. 5, 1109-1115 (2004).
106. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
107. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004).
108. Hatziioannou, T. et al. A macaque model of HIV-1 infection. Proc. Natl Acad. Sci. USA 106, 4425-4429 (2009).
109. Hatziioannou, T. et al. Generation of simian-tropic HIV-1 by restriction factor evasion. Science 314, 95 (2006).
110. Kamada, K. et al. Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells. Proc. Natl Acad. Sci. USA 103, 16959-16964 (2006).
111. Dudley, D. M., Wentzel, J. L., Lalonde, M. S., Veazey, R. S. & Arts, E. J. Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J. Virol. 83, 5067-5076 (2009).
112. Pekrun, K. et al. Evolution of a human immunodeficiency virus type 1 variant with enhanced replication in pig-tailed macaque cells by DNA shuffling. J. Virol. 76, 2924-2935 (2002).
113. Shibata, R. & Adachi, A. SIV/HIV recombinants and their use in studying biological properties. AIDS Res. Hum. Retroviruses 8, 403-409 (1992).
114. Box, G. E. P. & Draper, N. R. empirical Model-Building and Response Surfaces (Wiley, New York, 1987).
115. Xu, R. et al. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res. Hum. Retroviruses 22, 1022-1030 (2006).
116. Gorse, G. J. et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26, 215-223 (2008).
117. Subbramanian, R. A. et al. Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys. J. Virol. 77, 10113-10118 (2003).
118. Wilson, C. C. et al. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. Clin. Vaccine Immunol. 15, 986-994 (2008).
119. Nehete, P. N. et al. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIVKU2 infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology 370, 130-141 (2008).
120. Spearman, P. et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine 27, 243-249 (2009).
121. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
122. Casimiro, D. R. et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77, 6305-6313 (2003).
123. Priddy, F. H. et al. Safety and immunogenicity of a replication- incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769-1781 (2008).
124. Pal, R. et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76, 292-302 (2002).
125. Pal, R. et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J. Virol. 80, 3732-3742 (2006).
126. Villefroy, P. et al. SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251. Virol. J. 3, 65 (2006).
127. Letvin, N. L. et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530-1533 (2006).
128. Robinson, H. L. et al. Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-γ, IL-2, and TNF-α coproducing CD4 and CD8 T cells. AIDS Res. Hum. Retroviruses 23, 1555-1562 (2007).
129. Weber, J. et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo. AIDS 15, 1563-1568 (2001).
130. Stephenson, J. HIV studies: progress in microbicides, dead end for an immune-boosting strategy. JAMA 301, 1421-1422 (2009).
131. Baden, L. R. et al. Phase I trials of a prophylactic HIV-1 gag vaccine with IL-12 or IL-15 DNA molecular adjuvant (HVTN 060 and 063). Antiviral Ther. 12, (Suppl. 4) P06-11 (2007).